Cargando…
Large numbers of patients are needed to obtain additional approvals for new cancer drugs: A retrospective cohort study
Patients endure risk and uncertainty when they participate in clinical trials. We previously estimated that 12,217 patient-participants are required to bring a new cancer drug to market. However, many development efforts are aimed at extending the label of already approved drugs. Herein, we estimate...
Autores principales: | Ouimet, Charlotte, Hutchinson, Nora, Wang, Catherine, Matyka, Carol, Del Paggio, Joseph C., Kimmelman, Jonathan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522579/ https://www.ncbi.nlm.nih.gov/pubmed/37752147 http://dx.doi.org/10.1038/s41598-023-42213-y |
Ejemplares similares
-
Diminishing clinical impact for post-approval cancer clinical trials: A retrospective cohort study
por: Ouimet, Charlotte, et al.
Publicado: (2022) -
Patient Participation in Clinical Trials of Oncology Drugs and Biologics Preceding Approval by the US Food and Drug Administration
por: Hutchinson, Nora, et al.
Publicado: (2021) -
The proportion of randomized controlled trials that inform clinical practice
por: Hutchinson, Nora, et al.
Publicado: (2022) -
Seek success, not approval: the only approval you need is yours
por: Elko, Kevin, et al.
Publicado: (2010) -
Number needed to treat for interleukin inhibitors approved for the treatment of moderate-to-severe plaque psoriasis in Italy
por: Ravasio, Roberto, et al.
Publicado: (2021)